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OBJECTIVE — An association of the C-857T polymorphism of the tumor necrosis factor-
(TNF-) gene promoter region with LDL cholesterol levels has been reported. This study was
designed to evaluate the relationship between the TNF--C-857T polymorphism and LDL
cholesterol levels according to statin treatment in subjects with type 2 diabetes.
RESEARCH DESIGN AND METHODS — DNA was obtained from 322 Japanese sub-
jects (160 male and 162 female) with type 2 diabetes, and TNF--C-857T polymorphisms were
determined by direct sequencing. Serum LDL cholesterol was measured by a direct method.
RESULTS — AlthoughserumLDLcholesterollevelsweresigniﬁcantlyhigherintheTcarriers
(C/T  T/T) than in the non–T carriers (C/C) (3.14  0.86 vs. 2.89  0.75 mmol/l, P  0.05),
there was no difference in LDL cholesterol levels between the non–T carriers and the T carriers
in statin-untreated subjects (2.87  0.73 vs. 2.89  0.76 mmol/l, NS), whereas in statin-treated
subjects, LDL cholesterol levels were signiﬁcantly higher in the T carriers than in the non–T
carriers (3.43  0.89 vs. 2.90  0.78 mmol/l, P  0.0007). There were no differences in HDL
cholesterol and triglyceride levels between the non–T carriers and the T carriers in both statin-
treated and -untreated subjects. The percent decrease in LDL cholesterol levels after adminis-
tration of statins was signiﬁcantly smaller in the T carriers compared with the non–T carriers
(27.6 vs. 36.4%, P  0.031).
CONCLUSIONS — The mutant allele of the C-857T promoter polymorphism of the TNF-
gene may predispose to resistance to the LDL cholesterol–lowering effect of statins and could be
one of the markers used to predict the efﬁcacy of statins.
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T
umor necrosis factor- (TNF-)i sa
potent immunomodulator and
proinﬂammatory cytokine with
multiple functions and plays a variety of
roles in pathological and physiological
conditions. There have been many re-
ports on relationships between TNF-
genepolymorphismsandvariousdiseases
including infectious and metabolic disor-
ders (1,2). Regarding lipid metabolism,
there have been a few reports on an asso-
ciation of TNF- gene polymorphism
with serum lipids including cholesterol
levels, the most potent risk factor for car-
diovasculardiseases(3–5).Shiauetal.(4)
have shown that TNF--G-238A is asso-
ciated with LDL cholesterol levels in Tai-
wanese patients with type 2 diabetes. We
have recently reported that TNF--C-
857T, a functional TNF- gene promoter
polymorphism with higher transcrip-
tional activity (6), was associated with
higher LDL cholesterol levels and carotid
plaques in Japanese subjects with type 2
diabetes (5). In the course of this study,
our preliminary analysis indicated that an
associationofTNF--C-857Twithhigher
LDL cholesterol levels was observed only
in subjects treated with the 3-hydroxy-3-
methylglutaryl (HMG)-CoA reductase in-
hibitors(statins),butnotinthosewithout
statin treatment (7), implying that this
polymorphism is resistant to the effect of
statins.Wethereforeperformedastudyto
conﬁrm that the C-857T promoter poly-
morphism of the TNF- gene is associ-
ated with resistance to the cholesterol-
loweringeffectofstatinsintype2diabetic
subjects.
RESEARCH DESIGN AND
METHODS— After obtaining approv-
al from the ethics committee of Iwate
Medical University and informed consent
fromallsubjects,bloodsampleswerecol-
lected from 322 type 2 diabetic subjects
(160 male and 162 female). All subjects
were Japanese. The present study was
performed in accordance with the guide-
lines expressed in the Declaration of
Helsinki.
Identiﬁcation of polymorphisms
Genomic DNAs were obtained from pe-
ripheral blood leukocytes by standard
phenol-chloroform extraction and etha-
nol precipitation methods or by the Bio-
mek 3000 Laboratory Automation Sys-
tem (Beckman-Coulter, Fullerton, CA).
The 5-ﬂanking region of the TNF-
gene, spanning from 188 to 1,229,
relative to the TNF- transcription start
site, was ampliﬁed by PCR using a Gene-
Amp PCR System 9700 (Applied Biosys-
tems, Foster City, CA). The PCR primers
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GTGTGTGTGTCTGG-3 and antisense
5-GGACACACAAGCATCAAGG-3.
PCRconditionswereasfollows(6):dena-
turing at 94°C for 1 min, annealing at
55°C for 2 min, extension at 72°C for 3
min, for 40 cycles, ﬁnal incubation at
72°C for 10 min, and cooling to 4°C. The
PCRproductswerepuriﬁedusingNucleo-
Spin Extract (Macherey-Nagel, Duren,
Germany). Sequence analysis was per-
formed using a BigDye Terminator v3.1
Cycle Sequencing Kit (PerkinElmer, Nor-
walk, CT) with the sequence primer 5-
TGTGGCCATATCTTCTTAAA-3 to
analyze the sequence from 782 to
1,209 for polymorphisms at 857,
863, and 1,031. Finally, the cycle se-
quencing products were puriﬁed again
with a Dye Terminator Removal Kit (AB-
gene House, Epsom, Surrey, U.K.) and
analyzed by a Prism 3100 Genetic Ana-
lyzer (Applied Biosystems), according to
the manufacturer’s instructions.
Laboratory examinations
For all subjects, blood was obtained after
fasting for 12 h, and blood cell counts,
fasting plasma glucose levels, fasting in-
sulin (immunoreactive insulin) levels,
A1C, total cholesterol, triglyceride, HDL
cholesterol, and LDL cholesterol were
measuredattheCentralLaboratoryinour
hospital.
Statistics
DataareexpressedasmeansSD.Statis-
tical signiﬁcance was analyzed by un-
paired t test and 
2 test using StatView-
J5.0 (Abacus Concepts, Berkeley, CA).
Signiﬁcance was considered at P  0.05.
RESULTS
Serum LDL cholesterol levels are
higher in diabetic subjects with the
T allele of the TNF--C-857T
promoter gene polymorphism than
in those with the C allele
ThefrequenciesofCandTallelesofTNF-
-C-857T were 85.1 and 14.9%, respec-
tively, which are not signiﬁcantly
different from those reported in the Japa-
nesepopulation(5,6,8).Hardy-Weinberg
equilibrium was maintained in this pop-
ulation.Wereconﬁrmedourpreviousob-
servation (5) for double the number of
instancesinwhichtheTcarriers(C/Tand
T/T) displayed signiﬁcantly higher serum
LDL cholesterol levels than the noncarri-
ers (C/C) (3.14  0.86 vs. 2.89  0.75
mmol/l, P  0.05) (Table 1). Clinical
backgrounds, such as sex and age distri-
butions, physiques, blood pressures,
A1C, and serum lipid levels other than
LDLcholesterolshowednodifferencebe-
tween these groups (Table 1) nor did the
baseline characteristics of medication for
dyslipidemia, diabetes, and hypertension
(Table 2). Other promoter polymor-
phisms of the TNF- gene, including
C-863A and T-1031C, were not associ-
ated with the serum LDL cholesterol lev-
els (data not shown).
Higher LDL cholesterol level in the T
carriers of the TNF--C-857T
polymorphism is observed in
subjects treated with statins but not
in those without statins
Because statins affect LDL cholesterol lev-
els, we divided subjects according to sta-
tin treatment and compared the serum
LDL cholesterol levels between the T car-
riers and the non–T carriers in those with
andwithoutstatintreatment.Asshownin
Table 1, the T carriers with statin treat-
ment displayed signiﬁcantly higher LDL
cholesterol levels than the non–T carriers
(3.430.89vs.2.900.78mmol/l,P
0.0007), whereas in subjects without sta-
tin treatment the LDL cholesterol levels
did not differ irrespective of genotype.
Other clinical characteristics did not dif-
fer between the T carriers and non–T car-
riers in statin-treated and -untreated
subjects(Table1).Thedistributionofuse
of statin subclasses including atorvasta-
tin, pitavastatin, pravastatin, ﬂuvastatin,
and rosuvastatin was not different be-
Table 2—Comparison of medications in diabetic subjects between the TNF--C-857T
polymorphisms
C/C C/T, T/T P
Statins (without/with) 136/95 49/42 NS
Fibrates (without/with) 228/3 90/1 NS
Oral hypoglycemic drugs (without/with) 50/181 22/69 NS
Insulin (without/with) 136/95 49/42 NS
Hypotensive drugs (without/with) 115/72 26/29 NS
Table 1—Comparison of clinical characteristics of diabetic subjects according to the TNF--C-857T polymorphism and statin treatment
All subjects
Subjects without statin
treatment
Subjects with statin
treatment
C/C C/T,T/T C/C C/T,T/T C/C C/T,T/T
Sex (male/female) 116/115 44/47 77/59 29/20 39/56 15/27
Age (years) 62.9  10.9 62.2  13.6 62.3  11.7 62.3  15.8 63.4  9.6 61.9  11.0
Height (cm) 158.6  8.8 156.7  15.4 159.3  9.2 159.1  8.7 157.5  8.4 156.3  8.7
Body wt (kg) 62.5  11.8 61.5  12.4 61.2  11.6 60.9  12.6 63.4  13.9 62.5  12.4
BMI (kg/m²) 24.8  4.0 24.1  3.5 23.8  4.1 23.8  3.6 25.9  4.2 24.8  3.4
Systolic blood pressure (mmHg) 134.8  19.9 134.1  17.7 136.2  21.5 132.3  18.1 134.9  18.1 136.8  17.6
Diastolic blood pressure (mmHg) 78.0  13.3 74.9  11.6 78.8  13.9 73.4  10.6 76.1  12.4 76.5  12.9
A1C (%) 7.64  1.73 7.39  1.65 7.72  1.91 7.52  1.70 7.59  1.46 7.30  1.60
Total cholesterol (mmol/l) 5.05  0.92 5.21  1.02 4.95  0.82 4.83  0.86 5.18  1.05 5.68  1.01*
Triglycerides (mmol/l) 1.51  0.95 1.52  0.83 1.39  0.94 1.34  0.88 1.51  0.84 1.58  0.68
HDL cholesterol (mmol/l) 1.45  0.45 1.48  0.45 1.44  0.46 1.46  0.49 1.46  0.43 1.53  0.40
LDL cholesterol (mmol/l) 2.89  0.75 3.14  0.86* 2.87  0.73 2.89  0.76 2.90  0.78 3.43  0.89†
Data are means  SD. *P  0.05 (vs. C/C); †P  0.0001 (vs. C/C).
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the statin-treated subjects (data not
shown).
T carriers of the TNF--C-857T
polymorphism are more resistant to
the LDL cholesterol–lowering effect
of statin treatment than non–T
carriers
Table 1 indicates the possibility of a dif-
ference in the LDL cholesterol–lowering
effectofstatinsbetweentheTcarriersand
the non–T carriers. To see whether the T
carriers are resistant to the statin treat-
ment, we retrospectively analyzed the
LDL cholesterol levels before and 3–6
months after statin administration among
a subset of the diabetic subjects with hy-
percholesterolemia, whose complete
datasets were available for analysis. As
shown in Fig. 1, the percent reduction in
LDL cholesterol levels after statin admin-
istration was signiﬁcantly smaller in the T
carriersthaninthenon–Tcarriers(27.6
vs. 36.4%, P  0.031).
CONCLUSIONS — In this clinical
observation, our data indicate for the ﬁrst
time that the C-857T polymorphism in
the promoter region of the TNF- gene is
associated with serum LDL cholesterol
levels in statin-treated subjects with type
2 diabetes and the T carrier is resistant to
statin treatment.
We have conﬁrmed that T carriers
displayed higher serum LDL cholesterol
levels consistent with our previous report
(5), after doubling the number of sub-
jects. The T allele of TNF--C-857T gen-
erates signiﬁcantly higher transcriptional
promoter activity than the C allele does,
possibly leading to elevated TNF- pro-
duction (6,9). The administration of
TNF- in rodents is followed by an in-
crease in serum concentrations of total
cholesterol and hepatic cholesterol syn-
thesis (10), probably by stimulating the
activity of HMG-CoA reductase (11).
However, in our human subjects, the in-
crease in HMG-CoA reductase activity is
not a mechanism of the increased serum
LDL cholesterol in the T carriers of TNF-
-C-857T, because there was no differ-
ence in LDL cholesterol levels between
the T carriers and non–T carriers, who
were not treated with statins (Table 1).
A further analysis revealed that the
C-857Tpromoterpolymorphismaffected
the cholesterol-lowering effect of statins
but did not have a direct effect on choles-
terol synthesis. T carriers taking statins
displayed signiﬁcantly higher serum LDL
cholesterol levels but those who were not
taking statins did not (Table 1), indicat-
ing that TNF- productivity possibly af-
fects sensitivity to the LDL cholesterol–
lowering effects of statins. Indeed, the T
carriers exhibited a signiﬁcantly smaller
LDL cholesterol–lowering rate in re-
sponsetostatintreatmentthanthenon–T
carriers (Fig. 1). Fibrates, other drugs
affecting the lipid proﬁle, probably did
not inﬂuence our results, because very
few subjects were treated with ﬁbrates
(Table 2).
Statinsaresubstratesofseveraldrug
transporters (12), including the inﬂux trans-
portersolutecarrierorganicaniontransporter
family, member 1B1 (SLCO1B1, previously
known as OATP1B1/OATP-C/OATP2/LST-
1)(13–15).Itisreasonabletoassumethat
impaired function or expression of the
transporters would result in reduced he-
patic uptake of statins and then in re-
duced cholesterol-lowering efﬁcacy
because of lower intracellular statin con-
centrationsofhepatocytes.TNF-report-
edly suppressed protein expression and
transport activity of SLCO1B1 (16), which
is located on the sinusoidal membrane
of hepatocytes (17). This molecule plays
a pivotal role as a major transporter of
various statins, including atorvastatin,
simvastatin, pitavastatin, pravastatin, ﬂu-
vastatin, and rosuvastatin (13–15), from
the portal blood into hepatocytes. In
fact, a retrospective study in Caucasian
subjectssuggestedaweakereffectofprav-
astatin on inhibition of cholesterol syn-
thesisamongcarriersoftheSLCO1B1*17
haplotype, which is associated with im-
paired OATPB1B function and/or expres-
sion (18). Therefore, T alleles of the TNF-
-C-857T polymorphism with the higher
promoter transcriptional activities (6,9)
possibly result in a reduced LDL choles-
terol–lowering effect of statins, which
may be in line with our present observa-
tion. However, the serum concentration
of TNF- was not signiﬁcantly higher in
the T carriers of the C-857T than in the
non–T carriers (5), probably because of
dilution of TNF- in circulation com-
pared with those in local region. The
lower hepatic statin concentrations in the
T carriers associated with defective func-
tion and/or expression of OATPB1B re-
mains to be proven. We could not ﬁnd
differences in the proportion of the med-
icinesusedsuchashydrophilic(pravasta-
tin and rosuvastatin) and lipophilic
(atorvastatin, simvastatin, pitavastatin,
and ﬂuvastatin) statins or statins with
weak or strong cholesterol-lowering ef-
fectbetweentheTcarriersandnon–Tcar-
rier, although the number of patients was
small (data not shown).
It is possible, as mentioned above,
that the TNF- gene polymorphism is in-
volved in the sensitivity to the LDL cho-
lesterol–lowering effect of statins via
TNF-productivity.However,otherpos-
sibilitiesincludinglinkagedisequilibrium
of this polymorphism with a susceptibil-
ity gene to the effect of statins cannot be
ruled out.
In summary, these results strongly
suggest that the mutant allele of the
C-857T promoter polymorphism of the
TNF- gene may predispose to resistance
to the LDL cholesterol–lowering effect of
statins and then could be one of markers
to predict the efﬁcacy of statins.
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Figure 1—Percent reduction of serum LDL
cholesterol (LDL-C) levels after statin treat-
ment according to the TNF--C-857T poly-
morphism. Percent reduction  ([LDL
cholesterol levels before statin treatment] 
[LDLcholesterollevels3–6monthsafterstatin
treatment])/[LDL cholesterol levels before sta-
tin treatment] 	 100. Percent reductions in
C/CandC/T,T/Twere36.4and27.6%,re-
spectively (P  0.031).
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